Mallak joined MSD in 2002 and has been in his current role since 2021. In June 2024, the company signed its fourth MoU with the Department of Health – Abu Dhabi (DoH) to expand clinical research activities, specifically targeting lung cancer trials in the Emirate. In December 2024, MSD introduced a treatment for Pulmonary Arterial Hypertension (PAH), making the U.A.E. the first in the region to provide access to patients living with this rare disease through the DoH. Mallak is Vice President of PhRMAG and a member of AmCham’s Dubai’s Board of Directors. He also leads DE&I initiatives across EEMEA at MSD and served on the PhRMAG Executive Committee.